Publications by authors named "Nancy U Lin"

100Publications

Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center.

Breast Cancer Res Treat 2020 Sep 16. Epub 2020 Sep 16.

Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05931-9DOI Listing
September 2020

Response of Brain Metastases From -Mutant Breast Cancer to Alpelisib.

JCO Precis Oncol 2020 27;4. Epub 2020 May 27.

Beth Israel Deaconess Medical Center, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/PO.19.00403DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446424PMC
May 2020

Response to Letter to Editor.

Neuro Oncol 2020 Aug 21. Epub 2020 Aug 21.

UCLA Brain Tumor Imaging Laboratory, Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noaa202DOI Listing
August 2020

Barriers to Clinical Trial Accrual: Perspectives of Community-Based Providers.

Clin Breast Cancer 2020 May 7. Epub 2020 May 7.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2020.05.001DOI Listing
May 2020

Subtype switching in breast cancer brain metastases: a multicenter analysis.

Neuro Oncol 2020 Aug;22(8):1173-1181

Computational Neuroscience Outcomes Center, Department of Neurosurgery, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noaa013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471502PMC
August 2020

Systemic therapy following craniotomy in patients with a solitary breast cancer brain metastasis.

Breast Cancer Res Treat 2020 Feb 17;180(1):147-155. Epub 2020 Jan 17.

Division of Breast Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05531-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7031200PMC
February 2020

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.

N Engl J Med 2020 02 11;382(7):597-609. Epub 2019 Dec 11.

From M.D. Anderson Cancer Center, Houston (R.K.M., G.H.); Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (S. Loi); the Royal Marsden NHS Foundation Trust, London (A.O.), and Edinburgh Cancer Research Centre, Edinburgh (D.C.) - both in the United Kingdom; Winship Cancer Institute, Atlanta (E.P.); Sarah Cannon Research Institute/Tennessee Oncology-Nashville (E.H.) and Vanderbilt University Medical Center (V.A.), Nashville; University of California, Los Angeles, Medical Center-Jonsson Comprehensive Cancer Center, Los Angeles (S.A.H., D.S.), and Stanford Comprehensive Cancer Institute, Palo Alto (M.P.) - both in California; Dana-Farber Cancer Institute, Boston (N.U.L., I.K., E.P.W.); University of Colorado Cancer Center, Aurora (V.B.); Duke Cancer Institute, Durham (C.A.), and University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill (L.A.C.) - both in North Carolina; University Health Network, Princess Margaret Cancer Centre, Toronto (P.L.B.), and British Columbia Cancer, Vancouver (K.G.) - both in Canada; Hospital Universitario Vall D'Hebron, Barcelona (M.O.); Sygehus Lillebaelt-Vejle Sygehus, Vejle, Denmark (E.J.); Centre Léon Bérard, Lyon, France (T.B.); Rambam Health Care Campus, Haifa, Israel (S.S.S.); Universitaetsklinikum Hamburg-Eppendorf, Hamburg (V.M.), and German Breast Group, Neu-Isenburg (S. Loibl) - both in Germany; Hospital Cuf Descobertas R. Mário Botas, Lisbon, Portugal (S.B.); Cliniques Universitaires Saint-Luc, Brussels (F.P.D.); Third Medical Department, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials, and Cancer Cluster Salzburg, Salzburg, Austria (R.G.); Istituto Europeo di Oncologia, IRCCS, University of Milan, Milan (G.C.); and Seattle Genetics, Bothell, WA (M.C.P.-W., L.W., W.F.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1914609DOI Listing
February 2020

Response to Olaparib in a Patient with Germline Mutation and Breast Cancer Leptomeningeal Carcinomatosis.

NPJ Breast Cancer 2019 29;5:46. Epub 2019 Nov 29.

1Medical Oncology, Dana-Farber Cancer Institute, Boston, MA USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41523-019-0139-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884546PMC
November 2019

Aggressive Subsets of Metastatic Triple Negative Breast Cancer.

Clin Breast Cancer 2020 02 31;20(1):e20-e26. Epub 2019 Jul 31.

Department of Medicine, Ohio State University College of Medicine, Columbus, OH; Division of Medical Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.06.012DOI Listing
February 2020

Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.

Cancer 2020 01 3;126(2):271-280. Epub 2019 Oct 3.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32540DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003745PMC
January 2020

A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases.

Breast Cancer Res Treat 2020 Jan 20;179(1):113-123. Epub 2019 Sep 20.

Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05445-zDOI Listing
January 2020

Correction to: Systemic Therapy of Central Nervous System Metastases of Breast Cancer.

Curr Oncol Rep 2019 May 17;21(7):59. Epub 2019 May 17.

Department of Medical Oncology, Division of Breast Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave., Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-019-0813-3
Publisher Site
http://dx.doi.org/10.1007/s11912-019-0813-3DOI Listing
May 2019

Prognostic Value of Brain Metastasis-Free Interval in Patients with Breast Cancer Brain Metastases.

World Neurosurg 2019 Aug 26;128:e157-e164. Epub 2019 Apr 26.

Department of Neurosurgery, Computational Neuroscience Outcomes Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Department of Neurosurgery, Leiden University Medical Center, Leiden, Zuid-Holland, the Netherlands; Department of Neurosurgery, Haaglanden Medical Center, The Hague, the Netherlands; Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S18788750193106
Publisher Site
http://dx.doi.org/10.1016/j.wneu.2019.04.072DOI Listing
August 2019

Breast cancer subtype and intracranial recurrence patterns after brain-directed radiation for brain metastases.

Breast Cancer Res Treat 2019 Jul 13;176(1):171-179. Epub 2019 Apr 13.

Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-019-05236-6
Publisher Site
http://dx.doi.org/10.1007/s10549-019-05236-6DOI Listing
July 2019

Systemic Therapy of Central Nervous System Metastases of Breast Cancer.

Curr Oncol Rep 2019 04 8;21(6):49. Epub 2019 Apr 8.

Department of Medical Oncology, Division of Breast Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave., Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0802-6DOI Listing
April 2019

Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment.

Cancer Discov 2019 02 24;9(2):176-198. Epub 2019 Jan 24.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-18-1177DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387871PMC
February 2019

Update on managing brain metastases in breast cancer.

Authors:
Nancy U Lin

Clin Adv Hematol Oncol 2018 Sep;16(9):598-601

Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
September 2018

Increasing Burden of Prior Authorizations in the Delivery of Oncology Care in the United States.

J Oncol Pract 2018 09 20;14(9):525-528. Epub 2018 Aug 20.

Dana-Farber Cancer Institute, Boston, MA; and Marin Cancer Care, Greenbrae, CA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JOP.18.00428
Publisher Site
http://dx.doi.org/10.1200/JOP.18.00428DOI Listing
September 2018

Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update Summary.

J Oncol Pract 2018 08 10;14(8):505-507. Epub 2018 Jul 10.

University of Florida Health Cancer Center at Orlando Health, Orlando, FL; American Society of Clinical Oncology, Alexandria, VA; and Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.18.00291DOI Listing
August 2018

Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update.

J Clin Oncol 2018 09 25;36(27):2804-2807. Epub 2018 Jun 25.

Naren Ramakrishna, University of Florida Health Cancer Center at Orlando Health, Orlando; Jennifer Levinson, Ponte Vedra Beach, FL; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance, Seattle, WA; Nancy E. Davidson, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA; Sharon H. Giordano, University of Texas MD Anderson Cancer Center, Houston; Debra A. Patt, Texas Oncology, Austin, TX; Ian E. Krop, Eric P. Winer, and Nancy U. Lin, Dana-Farber Cancer Institute, Boston, MA; and Jane Perlmutter, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.79.2713DOI Listing
September 2018

Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update.

J Clin Oncol 2018 09 25;36(26):2736-2740. Epub 2018 Jun 25.

Sharon H. Giordano, The University of Texas MD Anderson, Houston; Debra A. Patt, Texas Oncology, Austin, TX; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance; Nancy E. Davidson, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA; Ian E. Krop, Nancy U. Lin, and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Jennifer Levinson, Ponte Vedra Beach; Naren Ramakrishna, Orlando Health University of Florida Health Cancer Center, Orlando, FL; and Jane Perlmutter, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.79.2697DOI Listing
September 2018

Breast cancer-specific survival by age: Worse outcomes for the oldest patients.

Cancer 2018 05 2;124(10):2184-2191. Epub 2018 Mar 2.

Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31308DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935594PMC
May 2018

Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain?

Clin Cancer Res 2018 04 6;24(8):1795-1804. Epub 2018 Feb 6.

Department of Cancer Biology, Dana Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-17-3351DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5899637PMC
April 2018

Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States.

Breast Cancer Res Treat 2018 Apr 13;168(3):727-737. Epub 2018 Jan 13.

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-018-4659-4DOI Listing
April 2018

Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer.

J Clin Oncol 2018 02 3;36(6):543-553. Epub 2018 Jan 3.

Daniel G. Stover, Ohio State University Comprehensive Cancer Center, Columbus, OH; Heather A. Parsons, Gavin Ha, William T. Barry, Hao Guo, Atish D. Choudhury, Melissa E. Hughes, Deborah A. Dillon, Ann H. Partridge, Nikhil Wagle, Ian E. Krop, Todd R. Golub, Eric P. Winer, Sara M. Tolaney, and Nancy U. Lin, Dana-Farber Cancer Institute; Gad Getz, Massachusetts General Hospital, Boston; Gavin Ha, Samuel S. Freeman, Atish D. Choudhury, Gregory Gydush, Sarah C. Reed, Justin Rhoades, Denisse Rotem, Nikhil Wagle, Gad Getz, Todd R. Golub, and Viktor A. Adalsteinsson, Broad Institute of Harvard and Massachusetts Institute of Technology; and J. Christopher Love, Massachusetts Institute of Technology, Cambridge, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.0033DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815405PMC
February 2018

Treatment adoption and relative effectiveness of aromatase inhibitors compared to tamoxifen in early breast cancer: A multi-institutional observational study.

Breast 2018 Feb 10;37:107-113. Epub 2017 Nov 10.

Institut Gustave Roussy, Unit INSERM 981, 114 Rue Edouard Vaillant, 94800 Villejuif, France; Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2017.11.003DOI Listing
February 2018

Attitudes of patients with metastatic cancer towards research biopsies.

Asia Pac J Clin Oncol 2018 Jun 6;14(3):231-238. Epub 2017 Nov 6.

University of New South Wales, Kensington, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.12783DOI Listing
June 2018

Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement.

J Clin Oncol 2017 Nov 2;35(33):3737-3744. Epub 2017 Oct 2.

Edward S. Kim, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; Suanna S. Bruinooge, Caroline Schenkel, and Richard L. Schilsky, ASCO, Alexandria, VA; Samantha Roberts, Marina Kozak, Jeff Allen, and Ellen Sigal, Friends of Cancer Research; Samantha Roberts, Genentech, Washington, DC; Gwynn Ison, Julia A. Beaver, Rajeshwari Sridhara, and Tatiana M. Prowell, US Food and Drug Administration, Silver Spring; Thomas S. Uldrick and Andrea M. Denicoff, National Cancer Institute, Bethesda, MD; Nancy U. Lin, Dana-Farber Cancer Institute, Boston; Paul J. Hesketh, Lahey Health Cancer Institute, Burlington, MA; Lia Gore, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO; Stuart M. Lichtman, Memorial Sloan-Kettering Cancer Center, New York, NY; Nancy Roach, Fight Colorectal Cancer, Springfield, MO; Elizabeth Garrett-Mayer, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Eric Rubin, Merck Research Laboratories, Kenilworth, NJ; and Pratik Multani, Ignyta, San Diego, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.7916DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5692724PMC
November 2017

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group.

J Clin Oncol 2017 Nov 2;35(33):3760-3773. Epub 2017 Oct 2.

Nancy U. Lin, Dana-Farber Cancer Institute, Boston; Oliver Rosen, Deciphera Pharmaceuticals, Waltham, MA; Tatiana Prowell, Laleh Amiri-Kordestani, and Joohee Sul, US Food and Drug Administration, Silver Spring; Tatiana Prowell, Johns Hopkins Kimmel Cancer Center, Baltimore, MD; Antoinette R. Tan and Edward S. Kim, Carolinas HealthCare System, Charlotte, NC; Marina Kozak, Friends of Cancer Research; Louise Perkins, Melanoma Research Alliance, Washington, DC; Julia White, The Ohio State University, Columbus, OH; Katherine Beal, Memorial Sloan Kettering Cancer Center, New York, NY; and Richard Gaynor, Eli Lilly, Indianapolis, IN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.0761DOI Listing
November 2017

Implementation of Surgeon-Initiated Gene Expression Profile Testing (Onco type DX) Among Patients With Early-Stage Breast Cancer to Reduce Delays in Chemotherapy Initiation.

J Oncol Pract 2017 09 31;13(9):e815-e820. Epub 2017 Aug 31.

Dana-Farber Cancer Institute; Dana-Farber/Brigham and Women's Cancer Center; Brigham and Women's Hospital; and Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2017.023788DOI Listing
September 2017

Multiplexed Elimination of Wild-Type DNA and High-Resolution Melting Prior to Targeted Resequencing of Liquid Biopsies.

Clin Chem 2017 Oct 5;63(10):1605-1613. Epub 2017 Jul 5.

Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1373/clinchem.2017.272849DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914173PMC
October 2017

Breast Cancer in the Central Nervous System: Multidisciplinary Considerations and Management.

Am Soc Clin Oncol Educ Book 2017 ;37:45-56

From the Breast Oncology Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, CO; Department of Neuro-Oncology, University of Turin and City of Health and Science Hospital, Turin, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_175338DOI Listing
December 2017

Reply to Garcia J. et al.

Breast 2017 08 11;34:132. Epub 2017 May 11.

Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2017.05.003DOI Listing
August 2017

Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study.

Neuro Oncol 2017 Oct;19(11):1511-1521

Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts; Department of Biostatistics, Harvard T. H. Chan School of Public Health, and Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; Department of Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts; Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nox077DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5737512PMC
October 2017

Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer.

J Natl Compr Canc Netw 2017 03;15(3):316-324

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2017.0031DOI Listing
March 2017

Prior Authorization for Medications in a Breast Oncology Practice: Navigation of a Complex Process.

J Oncol Pract 2017 04 28;13(4):e273-e282. Epub 2017 Feb 28.

Dana-Farber Cancer Institute; and Boston University School of Medicine, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2016.017756DOI Listing
April 2017

Factors Associated With Delays in Chemotherapy Initiation Among Patients With Breast Cancer at a Comprehensive Cancer Center.

J Natl Compr Canc Netw 2016 12;14(12):1519-1526

From Department of Medical Oncology and Quality and Patient Safety, Dana-Farber Cancer Institute, Boston, Massachusetts; Oncoclinicas, Sao Paulo, Brazil; Department of General Surgery, Istanbul Medical School, Istanbul, Turkey; and Department of Surgery, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2016.0163DOI Listing
December 2016

Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study.

J Clin Oncol 2017 Mar 21;35(7):751-758. Epub 2016 Nov 21.

Kala Visvanathan, Johns Hopkins University School of Medicine and Bloomberg School of Public Health; MaryJo S. Fackler, Zhe Zhang, Zoila A. Lopez-Bujanda, Stacie C. Jeter, Lori J. Sokoll, Leslie M. Cope, Christopher B. Umbricht, David M. Euhus, Saraswati Sukumar, and Antonio C. Wolff, Johns Hopkins University School of Medicine, Baltimore, MD; Elizabeth Garrett-Mayer, Medical University of South Carolina, Charleston, SC; Andres Forero, University of Alabama at Birmingham, Birmingham, AL; Anna M. Storniolo, Indiana University, Bloomington, IN; Rita Nanda, University of Chicago, Chicago, IL; Nancy U. Lin, Dana-Farber Cancer Institute, Boston, MA; Lisa A. Carey, University of North Carolina, Chapel Hill, NC; and James N. Ingle, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.66.2080DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455421PMC
March 2017

Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab.

Breast Cancer Res Treat 2016 08 2;159(1):151-62. Epub 2016 Aug 2.

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-016-3927-4DOI Listing
August 2016

Imaging in the evaluation and follow-up of early and advanced breast cancer: When, why, and how often?

Breast 2017 Feb 13;31:318-324. Epub 2016 Jul 13.

Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2016.06.017DOI Listing
February 2017

Updates in the management of brain metastases.

Neuro Oncol 2016 08;18(8):1043-65

St. Luke's Radiation Oncology Associates, St. Luke's Cancer Center, Whiteside Institute for Clinical Research and University of Minnesota Duluth, Duluth, Minnesota (N.D.A.); Center for Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center, Boston, Massachusetts (E.Q.L., P.Y.W.); Harvard Medical School, Boston, Massachusetts (E.Q.L., B.M.A., N.U.L., I.F.D., P.Y.W.); Department of Radiation Oncology, University of Maryland Medical Center, Baltimore, Maryland (M.P.M.); Department of Medical Oncology, City of Hope, Duarte, California (K.M.); Department of Radiation Oncology, Dana-Farber/Brigham & Women's Cancer Center, Boston, Massachusetts (B.M.A.); Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts (N.U.L.); Department of Medicine, Division of Hematology-Oncology, University of North Carolina, Chapel Hill, North Carolina (C.K.A.); Department of Neurology/Neuro-Oncology, University of Turin, Turin, Italy (R.S.); Division of Medical Oncology, University of Colorado Denver, Denver, Colorado (D.R.C.); Department of Neurosurgery, Cleveland Clinic, Cleveland, Ohio (M.A.V.); Department of Neurosurgery, Brigham & Women's Hospital, Boston, Massachusetts (I.F.D.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/now127DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933491PMC
August 2016

Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis.

Breast Cancer Res Treat 2016 06 6;157(3):587-96. Epub 2016 Jun 6.

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-016-3845-5DOI Listing
June 2016

Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.

J Clin Oncol 2016 May 14;34(13):1460-8. Epub 2016 Mar 14.

Nadine Tung, Beth Israel Deaconess Medical Center; Nancy U. Lin, Eric P. Winer, and Judy E. Garber, Dana-Farber Cancer Institute; Nadine Tung, Nancy U. Lin, Eric P. Winer, and Judy E. Garber, Harvard Medical School, Boston, MA; and John Kidd, Brian A. Allen, Nanda Singh, Richard J. Wenstrup, and Anne-Renee Hartman, Myriad Genetic Laboratories, Inc., Salt Lake City, UT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.0747DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872307PMC
May 2016

Randomized trial of a physical activity intervention in women with metastatic breast cancer.

Cancer 2016 Apr 12;122(8):1169-77. Epub 2016 Feb 12.

Breast Oncology Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29899DOI Listing
April 2016

Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.

J Clin Oncol 2016 Mar 1;34(9):945-52. Epub 2016 Feb 1.

Rachel A. Freedman, Rebecca S. Gelman, Christina Herold, Nicole Ryabin, Sarah Farooq, Elizabeth Lawler, Ian E. Krop, Eric P. Winer, and Nancy U. Lin, Dana-Farber Cancer Institute; Beverly Moy, Massachusetts General Hospital; Alarice Lowe and Nathalie Y.R. Agar, Brigham and Women's Hospital, Boston, MA; Jeffrey S. Wefel, Kenneth R. Hess, and Nuhad Ibrahim, The University of Texas MD Anderson Cancer Center; Polly A. Niravath and Mothaffar F. Rimawi, Baylor College of Medicine, Houston, TX; Michelle E. Melisko, University of California, San Francisco, San Francisco, CA; Roisin M. Connolly and Antonio C. Wolff, Johns Hopkins University, Baltimore, MD; Catherine H. Van Poznak, University of Michigan, Ann Arbor, MI; Shannon L. Puhalla, University of Pittsburgh Cancer Institute and Magee-Women's Hospital, Pittsburgh, PA; Kimberly L. Blackwell, Duke University Medical Center, Durham, NC; and Minetta C. Liu, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2016/01/28/JCO.2015.63
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.63.0343
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.63.0343DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070554PMC
March 2016

Better treatments needed for breast cancer brain metastases.

Authors:
Nancy U Lin

Lancet Oncol 2015 Dec 17;16(16):1583-4. Epub 2015 Nov 17.

Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(15)00477-5DOI Listing
December 2015

Variation in Additional Breast Imaging Orders and Impact on Surgical Wait Times at a Comprehensive Cancer Center.

Ann Surg Oncol 2015 Dec 26;22 Suppl 3:S428-34. Epub 2015 Aug 26.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-015-4834-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4688062PMC
December 2015

Variation in the Attitudes of Medical Oncologists Toward Research Biopsies in Patients With Metastatic Breast Cancer.

Oncologist 2015 Sep 3;20(9):992-1000. Epub 2015 Aug 3.

Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA; Memorial Sloan Kettering Cancer Center, New York, New York, USA; Brigham and Women's Hospital, Boston, Massachusetts, USA; Massachusetts General Hospital, Boston, Massachusetts, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0112DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4571800PMC
September 2015

Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003).

J Clin Oncol 2015 Aug 13;33(24):2623-31. Epub 2015 Jul 13.

Nancy U. Lin, Hao Guo, Nicole Ryabin, Julie S. Najita, William T. Barry, Ian E. Krop, Eric P. Winer, and Annick D. Van den Abbeele, Dana-Farber Cancer Institute; Andrea L. Richardson and Annick D. Van den Abbeele, Brigham and Women's Hospital, Boston, MA; Jeffrey T. Yap, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Ingrid A. Mayer and Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN; Carla I. Falkson, University of Alabama, Birmingham, AL; Timothy J. Hobday, Mayo Clinic, Rochester, MN; E. Claire Dees, University of North Carolina, Chapel Hill, NC; Rita Nanda, University of Chicago, Chicago, IL; Mothaffar F. Rimawi, Baylor College of Medicine, Houston, TX; and Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.0353DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534525PMC
August 2015

Racial differences in outcomes for patients with metastatic breast cancer by disease subtype.

Breast Cancer Res Treat 2015 Jun 29;151(3):697-707. Epub 2015 May 29.

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-015-3432-1DOI Listing
June 2015

Informational needs and the quality of life of patients in their first year after metastatic breast cancer diagnosis.

J Community Support Oncol 2014 Oct;12(10):347-54

Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/jcso.0077DOI Listing
October 2014

Weighing the options for human epidermal growth factor receptor 2-directed therapy in metastatic breast cancer.

Authors:
Nancy U Lin

J Clin Oncol 2015 May 6;33(14):1530-3. Epub 2015 Apr 6.

Dana-Farber Cancer Institute, Boston, MA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.1427DOI Listing
May 2015